DVA Medical Fee Schedule Tracker

Showing 4601–4650 of 5886 Pg 93/118

	Item No.	Description	Category	MBS Fee	DVA Fee
	61473	Thyroid study (R)	Category 5 — Diagnostic Imaging	$190.75	$185.90 ▼
Item Number 61473 Fee Comparison MBS $190.75 → DVA $185.90 -$4.85 (-3%) Additional DVA Rates DI Fee $185.90 Full Description Thyroid study (R) Sign in to watch this code → Get an email alert when this item changes
	61477	—	—	—	$1019.55
Item Number 61477 Fee Comparison MBS — → DVA $1019.55 Additional DVA Rates DI Fee $1019.55 Sign in to watch this code → Get an email alert when this item changes
	61480	Parathyroid study (R)	Category 5 — Diagnostic Imaging	$420.65	$410.00 ▼
Item Number 61480 Fee Comparison MBS $420.65 → DVA $410.00 -$10.65 (-3%) Additional DVA Rates DI Fee $410.00 Full Description Parathyroid study (R) Sign in to watch this code → Get an email alert when this item changes
	61485	Adrenal study, with single photon emission tomography (R)	Category 5 — Diagnostic Imaging	$3658.00	$3565.30 ▼
Item Number 61485 Fee Comparison MBS $3658.00 → DVA $3565.30 -$92.70 (-3%) Additional DVA Rates DI Fee $3565.30 Full Description Adrenal study, with single photon emission tomography (R) Sign in to watch this code → Get an email alert when this item changes
	61495	Tear duct study (R)	Category 5 — Diagnostic Imaging	$242.60	$236.45 ▼
Item Number 61495 Fee Comparison MBS $242.60 → DVA $236.45 -$6.15 (-3%) Additional DVA Rates DI Fee $236.45 Full Description Tear duct study (R) Sign in to watch this code → Get an email alert when this item changes
	61499	Particle perfusion study (infra arterial) or Le Veen shunt study (R)	Category 5 — Diagnostic Imaging	$275.10	$268.15 ▼
Item Number 61499 Fee Comparison MBS $275.10 → DVA $268.15 -$6.95 (-3%) Additional DVA Rates DI Fee $268.15 Full Description Particle perfusion study (infra arterial) or Le Veen shunt study (R) Sign in to watch this code → Get an email alert when this item changes
	61505	CT scan performed at the same time and covering the same body area as single photon emission tomography or positron emission tomography for the purpose of anatomic localisation or attenuation correction if no separate diagnostic CT report is issued and performed in association with a service to which an item in Subgroup 1 or 2 of Group I4 applies (R)	Category 5 — Diagnostic Imaging	$100.00	$100.00
Item Number 61505 Fee Comparison MBS $100.00 → DVA $100.00 Additional DVA Rates DI Fee $100.00 Full Description CT scan performed at the same time and covering the same body area as single photon emission tomography or positron emission tomography for the purpose of anatomic localisation or attenuation correction if no separate diagnostic CT report is issued and performed in association with a service to which an item in Subgroup 1 or 2 of Group I4 applies (R) Sign in to watch this code → Get an email alert when this item changes
	61523	Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.(R)	Category 5 — Diagnostic Imaging	$953.00	$953.00
Item Number 61523 Fee Comparison MBS $953.00 → DVA $953.00 Additional DVA Rates DI Fee $953.00 Full Description Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.(R) Sign in to watch this code → Get an email alert when this item changes
	61524	Whole body FDG PET study, performed for the staging of locally advanced (Stage III) breast cancer, for a patient who is considered suitable for active therapy (R) (Anaes.)	Category 5 — Diagnostic Imaging	$953.00	$953.00
Item Number 61524 Fee Comparison MBS $953.00 → DVA $953.00 Additional DVA Rates DI Fee $953.00 Full Description Whole body FDG PET study, performed for the staging of locally advanced (Stage III) breast cancer, for a patient who is considered suitable for active therapy (R) (Anaes.) Sign in to watch this code → Get an email alert when this item changes
	61525	Whole body FDG PET study, performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma, for a patient who is considered suitable for active therapy (R) (Anaes.)	Category 5 — Diagnostic Imaging	$953.00	$953.00
Item Number 61525 Fee Comparison MBS $953.00 → DVA $953.00 Additional DVA Rates DI Fee $953.00 Full Description Whole body FDG PET study, performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma, for a patient who is considered suitable for active therapy (R) (Anaes.) Sign in to watch this code → Get an email alert when this item changes
	61527	Whole body study using PET, if the service is performed because the services to which items 61429, 61430, 61442, 61450 or 61453 apply cannot be performed due to unavailability of gallium-67 (R)	Category 5 — Diagnostic Imaging	$752.35	$752.35
Item Number 61527 Fee Comparison MBS $752.35 → DVA $752.35 Additional DVA Rates DI Fee $752.35 Full Description Whole body study using PET, if the service is performed because the services to which items 61429, 61430, 61442, 61450 or 61453 apply cannot be performed due to unavailability of gallium-67 (R) Sign in to watch this code → Get an email alert when this item changes
	61528	Whole body PSMA PET study, performed for the assessment of suitability for Lutetium 177 PSMA therapy in a patient with metastatic castrate resistant prostate cancer, after progressive disease has developed while undergoing prior treatment with at least one taxane chemotherapy and at least one androgen receptor signalling inhibitor. (R) (Anaes.)	Category 5 — Diagnostic Imaging	$1300.00	$1300.00
Item Number 61528 Fee Comparison MBS $1300.00 → DVA $1300.00 Additional DVA Rates DI Fee $1300.00 Full Description Whole body PSMA PET study, performed for the assessment of suitability for Lutetium 177 PSMA therapy in a patient with metastatic castrate resistant prostate cancer, after progressive disease has developed while undergoing prior treatment with at least one taxane chemotherapy and at least one androgen receptor signalling inhibitor. (R) (Anaes.) Sign in to watch this code → Get an email alert when this item changes
	61529	Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned (R)	Category 5 — Diagnostic Imaging	$953.00	$953.00
Item Number 61529 Fee Comparison MBS $953.00 → DVA $953.00 Additional DVA Rates DI Fee $953.00 Full Description Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned (R) Sign in to watch this code → Get an email alert when this item changes
	61530	Whole body 68Ga-DOTA-somatostatin receptor agonist PET study for: a) staging of histologically confirmed neuroendocrine neoplasm (NEN) considered surgically incurable on conventional imaging, orb) evaluation of somatostatin receptor expression of histologically confirmed and inoperable NEN, either locally advanced or metastatic, under consideration for peptide receptor radionuclide therapy (PRRT); orc) evaluation of response to PRRT therapy; ord) evaluation of suspected recurrent or metastatic disease in known somatostatin receptor positive NEN. (R) (Anaes.)	Category 5 — Diagnostic Imaging	$953.00	$953.00
Item Number 61530 Fee Comparison MBS $953.00 → DVA $953.00 Additional DVA Rates DI Fee $953.00 Full Description Whole body 68Ga-DOTA-somatostatin receptor agonist PET study for: a) staging of histologically confirmed neuroendocrine neoplasm (NEN) considered surgically incurable on conventional imaging, orb) evaluation of somatostatin receptor expression of histologically confirmed and inoperable NEN, either locally advanced or metastatic, under consideration for peptide receptor radionuclide therapy (PRRT); orc) evaluation of response to PRRT therapy; ord) evaluation of suspected recurrent or metastatic disease in known somatostatin receptor positive NEN. (R) (Anaes.) Sign in to watch this code → Get an email alert when this item changes
	61538	FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy. (R)	Category 5 — Diagnostic Imaging	$901.00	$901.00
Item Number 61538 Fee Comparison MBS $901.00 → DVA $901.00 Additional DVA Rates DI Fee $901.00 Full Description FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy. (R) Sign in to watch this code → Get an email alert when this item changes
	61541	Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy (R)	Category 5 — Diagnostic Imaging	$953.00	$953.00
Item Number 61541 Fee Comparison MBS $953.00 → DVA $953.00 Additional DVA Rates DI Fee $953.00 Full Description Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy (R) Sign in to watch this code → Get an email alert when this item changes
	61553	Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy (R)	Category 5 — Diagnostic Imaging	$999.00	$999.00
Item Number 61553 Fee Comparison MBS $999.00 → DVA $999.00 Additional DVA Rates DI Fee $999.00 Full Description Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy (R) Sign in to watch this code → Get an email alert when this item changes
	61559	FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery (R)	Category 5 — Diagnostic Imaging	$918.00	$918.00
Item Number 61559 Fee Comparison MBS $918.00 → DVA $918.00 Additional DVA Rates DI Fee $918.00 Full Description FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery (R) Sign in to watch this code → Get an email alert when this item changes
	61560	FDG PET study of the brain, performed for the diagnosis of Alzheimer’s disease, if: clinical evaluation of the patient by a specialist, or in consultation with a specialist, is equivocal; and the service includes a quantitative comparison of the results of the study with the results of an FDG PET study of a normal brain from a reference database; and a service to which this item applies has not been performed on the patient in the previous 12 months; and a service to which item 61402 applies has not been performed on the patient in the previous 12 months for the diagnosis or management of Alzheimer’s disease Applicable not more than 3 times per lifetime (R)	Category 5 — Diagnostic Imaging	$605.05	$605.05
Item Number 61560 Fee Comparison MBS $605.05 → DVA $605.05 Additional DVA Rates DI Fee $605.05 Full Description FDG PET study of the brain, performed for the diagnosis of Alzheimer’s disease, if: clinical evaluation of the patient by a specialist, or in consultation with a specialist, is equivocal; and the service includes a quantitative comparison of the results of the study with the results of an FDG PET study of a normal brain from a reference database; and a service to which this item applies has not been performed on the patient in the previous 12 months; and a service to which item 61402 applies has not been performed on the patient in the previous 12 months for the diagnosis or management of Alzheimer’s disease Applicable not more than 3 times per lifetime (R) Sign in to watch this code → Get an email alert when this item changes
	61563	Whole body prostate-specific membrane antigen PET study performed for the initial staging of intermediate to high-risk prostate adenocarcinoma, for a previously untreated patient who is considered suitable for locoregional therapy with curative intent Applicable once per lifetime (R)	Category 5 — Diagnostic Imaging	$1300.00	$1300.00
Item Number 61563 Fee Comparison MBS $1300.00 → DVA $1300.00 Additional DVA Rates DI Fee $1300.00 Full Description Whole body prostate-specific membrane antigen PET study performed for the initial staging of intermediate to high-risk prostate adenocarcinoma, for a previously untreated patient who is considered suitable for locoregional therapy with curative intent Applicable once per lifetime (R) Sign in to watch this code → Get an email alert when this item changes
	61564	Whole body prostate-specific membrane antigen PET study performed for the restaging of recurrent prostate adenocarcinoma, for a patient who:(a) has undergone prior locoregional therapy; and(b) is considered suitable for further locoregional therapy to determine appropriate therapeutic pathways and timing of treatment initiation Applicable twice per lifetime (R)	Category 5 — Diagnostic Imaging	$1300.00	$1300.00
Item Number 61564 Fee Comparison MBS $1300.00 → DVA $1300.00 Additional DVA Rates DI Fee $1300.00 Full Description Whole body prostate-specific membrane antigen PET study performed for the restaging of recurrent prostate adenocarcinoma, for a patient who:(a) has undergone prior locoregional therapy; and(b) is considered suitable for further locoregional therapy to determine appropriate therapeutic pathways and timing of treatment initiation Applicable twice per lifetime (R) Sign in to watch this code → Get an email alert when this item changes
	61565	Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy. (R)	Category 5 — Diagnostic Imaging	$953.00	$953.00
Item Number 61565 Fee Comparison MBS $953.00 → DVA $953.00 Additional DVA Rates DI Fee $953.00 Full Description Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy. (R) Sign in to watch this code → Get an email alert when this item changes
	61571	Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent. (R)	Category 5 — Diagnostic Imaging	$953.00	$953.00
Item Number 61571 Fee Comparison MBS $953.00 → DVA $953.00 Additional DVA Rates DI Fee $953.00 Full Description Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent. (R) Sign in to watch this code → Get an email alert when this item changes
	61575	Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent. (R)	Category 5 — Diagnostic Imaging	$953.00	$953.00
Item Number 61575 Fee Comparison MBS $953.00 → DVA $953.00 Additional DVA Rates DI Fee $953.00 Full Description Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent. (R) Sign in to watch this code → Get an email alert when this item changes
	61577	Whole body FDG PET study, performed for the staging of proven oesophageal or GEJ carcinoma, in patients considered suitable for active therapy (R).	Category 5 — Diagnostic Imaging	$953.00	$953.00
Item Number 61577 Fee Comparison MBS $953.00 → DVA $953.00 Additional DVA Rates DI Fee $953.00 Full Description Whole body FDG PET study, performed for the staging of proven oesophageal or GEJ carcinoma, in patients considered suitable for active therapy (R). Sign in to watch this code → Get an email alert when this item changes
	61598	Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head and neck cancer (R).	Category 5 — Diagnostic Imaging	$953.00	$953.00
Item Number 61598 Fee Comparison MBS $953.00 → DVA $953.00 Additional DVA Rates DI Fee $953.00 Full Description Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head and neck cancer (R). Sign in to watch this code → Get an email alert when this item changes
	61604	Whole body FDG PET study performed for the evaluation of patients with suspected residual head and neck cancer after definitive treatment, and who are suitable for active therapy (R).	Category 5 — Diagnostic Imaging	$953.00	$953.00
Item Number 61604 Fee Comparison MBS $953.00 → DVA $953.00 Additional DVA Rates DI Fee $953.00 Full Description Whole body FDG PET study performed for the evaluation of patients with suspected residual head and neck cancer after definitive treatment, and who are suitable for active therapy (R). Sign in to watch this code → Get an email alert when this item changes
	61610	Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes (R).	Category 5 — Diagnostic Imaging	$953.00	$953.00
Item Number 61610 Fee Comparison MBS $953.00 → DVA $953.00 Additional DVA Rates DI Fee $953.00 Full Description Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes (R). Sign in to watch this code → Get an email alert when this item changes
	61612	Whole body FDG PET study for the initial staging of cancer, for a patient who is considered suitable for active therapy, if:(a) the cancer is a typically FDG-avid cancer; and(b) there is at least 10% likelihood that a PET study result will inform a significant change in management for the patientApplicable once per cancer diagnosis (R)	Category 5 — Diagnostic Imaging	$953.00	$953.00
Item Number 61612 Fee Comparison MBS $953.00 → DVA $953.00 Additional DVA Rates DI Fee $953.00 Full Description Whole body FDG PET study for the initial staging of cancer, for a patient who is considered suitable for active therapy, if:(a) the cancer is a typically FDG-avid cancer; and(b) there is at least 10% likelihood that a PET study result will inform a significant change in management for the patientApplicable once per cancer diagnosis (R) Sign in to watch this code → Get an email alert when this item changes
	61614	Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent cancer in a patient who is undergoing, or is suitable for, active therapy, if the cancer is a typically FGD-avid cancer (R)	Category 5 — Diagnostic Imaging	$953.00	$953.00
Item Number 61614 Fee Comparison MBS $953.00 → DVA $953.00 Additional DVA Rates DI Fee $953.00 Full Description Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent cancer in a patient who is undergoing, or is suitable for, active therapy, if the cancer is a typically FGD-avid cancer (R) Sign in to watch this code → Get an email alert when this item changes
	61620	Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin or non-Hodgkin lymphoma (R)	Category 5 — Diagnostic Imaging	$953.00	$953.00
Item Number 61620 Fee Comparison MBS $953.00 → DVA $953.00 Additional DVA Rates DI Fee $953.00 Full Description Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin or non-Hodgkin lymphoma (R) Sign in to watch this code → Get an email alert when this item changes
	61622	Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin or non-Hodgkin lymphoma (R)	Category 5 — Diagnostic Imaging	$953.00	$953.00
Item Number 61622 Fee Comparison MBS $953.00 → DVA $953.00 Additional DVA Rates DI Fee $953.00 Full Description Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin or non-Hodgkin lymphoma (R) Sign in to watch this code → Get an email alert when this item changes
	61628	Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin or non-Hodgkin lymphoma (R)	Category 5 — Diagnostic Imaging	$953.00	$953.00
Item Number 61628 Fee Comparison MBS $953.00 → DVA $953.00 Additional DVA Rates DI Fee $953.00 Full Description Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin or non-Hodgkin lymphoma (R) Sign in to watch this code → Get an email alert when this item changes
	61632	Whole body FDG PET study to assess response to second-line chemotherapy if haemopoietic stem cell transplantation is being considered for Hodgkin or non-Hodgkin lymphoma (R)	Category 5 — Diagnostic Imaging	$953.00	$953.00
Item Number 61632 Fee Comparison MBS $953.00 → DVA $953.00 Additional DVA Rates DI Fee $953.00 Full Description Whole body FDG PET study to assess response to second-line chemotherapy if haemopoietic stem cell transplantation is being considered for Hodgkin or non-Hodgkin lymphoma (R) Sign in to watch this code → Get an email alert when this item changes
	61640	Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable. (R)	Category 5 — Diagnostic Imaging	$999.00	$999.00
Item Number 61640 Fee Comparison MBS $999.00 → DVA $999.00 Additional DVA Rates DI Fee $999.00 Full Description Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable. (R) Sign in to watch this code → Get an email alert when this item changes
	61644	Single rest myocardial perfusion study for the assessment of the extent and severity of non‑viable myocardium, with PET, if: (a) the service is performed because the service to which item 61325 applies cannot be performed due to unavailability of thallous chloride 201 (Tl-201); and (b) the patient has left ventricular systolic dysfunction and probable or confirmed coronary artery disease; and (c) the service is performed in conjunction with a rest myocardial perfusion study using technetium-99m; and (d) the service is requested by a specialist or a consultant physician; and (e) the service is not associated with a service to which item 11704, 11705, 11707, 11714, 11729 or 11730 applies; and (f) this service and item 61325 are applicable only twice each 24 months (R)	Category 5 — Diagnostic Imaging	$329.00	$329.00
Item Number 61644 Fee Comparison MBS $329.00 → DVA $329.00 Additional DVA Rates DI Fee $329.00 Full Description Single rest myocardial perfusion study for the assessment of the extent and severity of non‑viable myocardium, with PET, if: (a) the service is performed because the service to which item 61325 applies cannot be performed due to unavailability of thallous chloride 201 (Tl-201); and (b) the patient has left ventricular systolic dysfunction and probable or confirmed coronary artery disease; and (c) the service is performed in conjunction with a rest myocardial perfusion study using technetium-99m; and (d) the service is requested by a specialist or a consultant physician; and (e) the service is not associated with a service to which item 11704, 11705, 11707, 11714, 11729 or 11730 applies; and (f) this service and item 61325 are applicable only twice each 24 months (R) Sign in to watch this code → Get an email alert when this item changes
	61646	Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent. (R)	Category 5 — Diagnostic Imaging	$999.00	$999.00
Item Number 61646 Fee Comparison MBS $999.00 → DVA $999.00 Additional DVA Rates DI Fee $999.00 Full Description Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent. (R) Sign in to watch this code → Get an email alert when this item changes
	61647	Whole body 68Ga DOTA peptide PET study, if:(a) a gastro entero pancreatic neuroendocrine tumour is suspected on the basis of biochemical evidence with negative or equivocal conventional imaging; or(b) both:(i) a surgically amenable gastro entero pancreatic neuroendocrine tumour has been identified on the basis of conventional techniques; and(ii) the study is for excluding additional disease sites (R)	Category 5 — Diagnostic Imaging	$953.00	$953.00
Item Number 61647 Fee Comparison MBS $953.00 → DVA $953.00 Additional DVA Rates DI Fee $953.00 Full Description Whole body 68Ga DOTA peptide PET study, if:(a) a gastro entero pancreatic neuroendocrine tumour is suspected on the basis of biochemical evidence with negative or equivocal conventional imaging; or(b) both:(i) a surgically amenable gastro entero pancreatic neuroendocrine tumour has been identified on the basis of conventional techniques; and(ii) the study is for excluding additional disease sites (R) Sign in to watch this code → Get an email alert when this item changes
	61650	LeukoScan study of the long bones and feet for suspected osteomyelitis, if:(a) the patient does not have access to ex vivo white blood cell scanning; and(b) the patient is not being investigated for other sites of infection (R)	Category 5 — Diagnostic Imaging	$955.50	$931.30 ▼
Item Number 61650 Fee Comparison MBS $955.50 → DVA $931.30 -$24.20 (-3%) Additional DVA Rates DI Fee $931.30 Full Description LeukoScan study of the long bones and feet for suspected osteomyelitis, if:(a) the patient does not have access to ex vivo white blood cell scanning; and(b) the patient is not being investigated for other sites of infection (R) Sign in to watch this code → Get an email alert when this item changes
	63001	MRI—scan of head (including MRA, if performed) for tumour of the brain or meninges (R) (Contrast) (Anaes.)	Category 5 — Diagnostic Imaging	$463.80	$452.05 ▼
Item Number 63001 Fee Comparison MBS $463.80 → DVA $452.05 -$11.75 (-3%) Additional DVA Rates DI Fee $452.05 Full Description MRI—scan of head (including MRA, if performed) for tumour of the brain or meninges (R) (Contrast) (Anaes.) Sign in to watch this code → Get an email alert when this item changes
	63004	MRI—scan of head (including MRA, if performed) for inflammation of brain or meninges (R) (Contrast) (Anaes.)	Category 5 — Diagnostic Imaging	$463.80	$452.05 ▼
Item Number 63004 Fee Comparison MBS $463.80 → DVA $452.05 -$11.75 (-3%) Additional DVA Rates DI Fee $452.05 Full Description MRI—scan of head (including MRA, if performed) for inflammation of brain or meninges (R) (Contrast) (Anaes.) Sign in to watch this code → Get an email alert when this item changes
	63007	MRI—scan of head (including MRA, if performed) for skull base or orbital tumour (R) (Contrast) (Anaes.)	Category 5 — Diagnostic Imaging	$463.80	$452.05 ▼
Item Number 63007 Fee Comparison MBS $463.80 → DVA $452.05 -$11.75 (-3%) Additional DVA Rates DI Fee $452.05 Full Description MRI—scan of head (including MRA, if performed) for skull base or orbital tumour (R) (Contrast) (Anaes.) Sign in to watch this code → Get an email alert when this item changes
	63010	MRI—scan of head (including MRA, if performed) for stereotactic scan of brain, with fiducials in place, for the sole purpose of allowing planning for stereotactic neurosurgery (R) (Contrast) (Anaes.)	Category 5 — Diagnostic Imaging	$386.55	$376.75 ▼
Item Number 63010 Fee Comparison MBS $386.55 → DVA $376.75 -$9.80 (-3%) Additional DVA Rates DI Fee $376.75 Full Description MRI—scan of head (including MRA, if performed) for stereotactic scan of brain, with fiducials in place, for the sole purpose of allowing planning for stereotactic neurosurgery (R) (Contrast) (Anaes.) Sign in to watch this code → Get an email alert when this item changes
	63019	MRI—scan of head (including MRA if performed) for the assessment of suitability for the treatment of medically refractory essential tremor with magnetic resonance imaging‑guided focused ultrasound Applicable once per patient per lifetime (R) (Contrast) (Anaes.)	Category 5 — Diagnostic Imaging	$463.80	$452.05 ▼
Item Number 63019 Fee Comparison MBS $463.80 → DVA $452.05 -$11.75 (-3%) Additional DVA Rates DI Fee $452.05 Full Description MRI—scan of head (including MRA if performed) for the assessment of suitability for the treatment of medically refractory essential tremor with magnetic resonance imaging‑guided focused ultrasound Applicable once per patient per lifetime (R) (Contrast) (Anaes.) Sign in to watch this code → Get an email alert when this item changes
	63020	MRI—scan of head (including MRA if performed) for the post‑procedure assessment of the patient following magnetic resonance imaging‑guided focused ultrasound for the treatment of medically refractory essential tremor Applicable once per patient per lifetime (R) (Contrast) (Anaes.)	Category 5 — Diagnostic Imaging	$463.80	$452.05 ▼
Item Number 63020 Fee Comparison MBS $463.80 → DVA $452.05 -$11.75 (-3%) Additional DVA Rates DI Fee $452.05 Full Description MRI—scan of head (including MRA if performed) for the post‑procedure assessment of the patient following magnetic resonance imaging‑guided focused ultrasound for the treatment of medically refractory essential tremor Applicable once per patient per lifetime (R) (Contrast) (Anaes.) Sign in to watch this code → Get an email alert when this item changes
	63040	MRI—scan of head (including MRA, if performed) for acoustic neuroma (R) (Contrast) (Anaes.)	Category 5 — Diagnostic Imaging	$386.55	$376.75 ▼
Item Number 63040 Fee Comparison MBS $386.55 → DVA $376.75 -$9.80 (-3%) Additional DVA Rates DI Fee $376.75 Full Description MRI—scan of head (including MRA, if performed) for acoustic neuroma (R) (Contrast) (Anaes.) Sign in to watch this code → Get an email alert when this item changes
	63043	MRI—scan of head (including MRA, if performed) for pituitary tumour (R) (Contrast) (Anaes.)	Category 5 — Diagnostic Imaging	$412.25	$401.80 ▼
Item Number 63043 Fee Comparison MBS $412.25 → DVA $401.80 -$10.45 (-3%) Additional DVA Rates DI Fee $401.80 Full Description MRI—scan of head (including MRA, if performed) for pituitary tumour (R) (Contrast) (Anaes.) Sign in to watch this code → Get an email alert when this item changes
	63046	MRI—scan of head (including MRA, if performed) for toxic or metabolic or ischaemic encephalopathy (R) (Contrast) (Anaes.)	Category 5 — Diagnostic Imaging	$463.80	$452.05 ▼
Item Number 63046 Fee Comparison MBS $463.80 → DVA $452.05 -$11.75 (-3%) Additional DVA Rates DI Fee $452.05 Full Description MRI—scan of head (including MRA, if performed) for toxic or metabolic or ischaemic encephalopathy (R) (Contrast) (Anaes.) Sign in to watch this code → Get an email alert when this item changes
	63049	MRI—scan of head (including MRA, if performed) for demyelinating disease of the brain (R) (Contrast) (Anaes.)	Category 5 — Diagnostic Imaging	$463.80	$452.05 ▼
Item Number 63049 Fee Comparison MBS $463.80 → DVA $452.05 -$11.75 (-3%) Additional DVA Rates DI Fee $452.05 Full Description MRI—scan of head (including MRA, if performed) for demyelinating disease of the brain (R) (Contrast) (Anaes.) Sign in to watch this code → Get an email alert when this item changes
	63052	MRI—scan of head (including MRA, if performed) for congenital malformation of the brain or meninges (R) (Contrast) (Anaes.)	Category 5 — Diagnostic Imaging	$463.80	$452.05 ▼
Item Number 63052 Fee Comparison MBS $463.80 → DVA $452.05 -$11.75 (-3%) Additional DVA Rates DI Fee $452.05 Full Description MRI—scan of head (including MRA, if performed) for congenital malformation of the brain or meninges (R) (Contrast) (Anaes.) Sign in to watch this code → Get an email alert when this item changes

MBS Fee

$190.75

DVA Fee

$185.90

Category

Category 5 — Diagnostic Imaging

Description

Thyroid study (R)

DVA Fee

$1019.55

MBS Fee

$420.65

DVA Fee

$410.00

Category

Category 5 — Diagnostic Imaging

Description

Parathyroid study (R)

MBS Fee

$3658.00

DVA Fee

$3565.30

Category

Category 5 — Diagnostic Imaging

Description

Adrenal study, with single photon emission tomography (R)

MBS Fee

$242.60

DVA Fee

$236.45

Category

Category 5 — Diagnostic Imaging

Description

Tear duct study (R)

MBS Fee

$275.10

DVA Fee

$268.15

Category

Category 5 — Diagnostic Imaging

Description

Particle perfusion study (infra arterial) or Le Veen shunt study (R)

MBS Fee

$100.00

DVA Fee

$100.00

Category

Category 5 — Diagnostic Imaging

Description

CT scan performed at the same time and covering the same body area as single photon emission tomography or positron emission tomography for the purpose of anatomic localisation or attenuation correction if no separate diagnostic CT report is issued and performed in association with a service to which an item in Subgroup 1 or 2 of Group I4 applies (R)

MBS Fee

$953.00

DVA Fee

$953.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.(R)

MBS Fee

$953.00

DVA Fee

$953.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body FDG PET study, performed for the staging of locally advanced (Stage III) breast cancer, for a patient who is considered suitable for active therapy (R) (Anaes.)

MBS Fee

$953.00

DVA Fee

$953.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body FDG PET study, performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma, for a patient who is considered suitable for active therapy (R) (Anaes.)

MBS Fee

$752.35

DVA Fee

$752.35

Category

Category 5 — Diagnostic Imaging

Description

Whole body study using PET, if the service is performed because the services to which items 61429, 61430, 61442, 61450 or 61453 apply cannot be performed due to unavailability of gallium-67 (R)

MBS Fee

$1300.00

DVA Fee

$1300.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body PSMA PET study, performed for the assessment of suitability for Lutetium 177 PSMA therapy in a patient with metastatic castrate resistant prostate cancer, after progressive disease has developed while undergoing prior treatment with at least one taxane chemotherapy and at least one androgen receptor signalling inhibitor. (R) (Anaes.)

MBS Fee

$953.00

DVA Fee

$953.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned (R)

MBS Fee

$953.00

DVA Fee

$953.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body 68Ga-DOTA-somatostatin receptor agonist PET study for: a) staging of histologically confirmed neuroendocrine neoplasm (NEN) considered surgically incurable on conventional imaging, orb) evaluation of somatostatin receptor expression of histologically confirmed and inoperable NEN, either locally advanced or metastatic, under consideration for peptide receptor radionuclide therapy (PRRT); orc) evaluation of response to PRRT therapy; ord) evaluation of suspected recurrent or metastatic disease in known somatostatin receptor positive NEN. (R) (Anaes.)

MBS Fee

$901.00

DVA Fee

$901.00

Category

Category 5 — Diagnostic Imaging

Description

FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy. (R)

MBS Fee

$953.00

DVA Fee

$953.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy (R)

MBS Fee

$999.00

DVA Fee

$999.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy (R)

MBS Fee

$918.00

DVA Fee

$918.00

Category

Category 5 — Diagnostic Imaging

Description

FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery (R)

MBS Fee

$605.05

DVA Fee

$605.05

Category

Category 5 — Diagnostic Imaging

Description

FDG PET study of the brain, performed for the diagnosis of Alzheimer’s disease, if: clinical evaluation of the patient by a specialist, or in consultation with a specialist, is equivocal; and the service includes a quantitative comparison of the results of the study with the results of an FDG PET study of a normal brain from a reference database; and a service to which this item applies has not been performed on the patient in the previous 12 months; and a service to which item 61402 applies has not been performed on the patient in the previous 12 months for the diagnosis or management of Alzheimer’s disease Applicable not more than 3 times per lifetime (R)

MBS Fee

$1300.00

DVA Fee

$1300.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body prostate-specific membrane antigen PET study performed for the initial staging of intermediate to high-risk prostate adenocarcinoma, for a previously untreated patient who is considered suitable for locoregional therapy with curative intent Applicable once per lifetime (R)

MBS Fee

$1300.00

DVA Fee

$1300.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body prostate-specific membrane antigen PET study performed for the restaging of recurrent prostate adenocarcinoma, for a patient who:(a) has undergone prior locoregional therapy; and(b) is considered suitable for further locoregional therapy to determine appropriate therapeutic pathways and timing of treatment initiation Applicable twice per lifetime (R)

MBS Fee

$953.00

DVA Fee

$953.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy. (R)

MBS Fee

$953.00

DVA Fee

$953.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent. (R)

MBS Fee

$953.00

DVA Fee

$953.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent. (R)

MBS Fee

$953.00

DVA Fee

$953.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body FDG PET study, performed for the staging of proven oesophageal or GEJ carcinoma, in patients considered suitable for active therapy (R).

MBS Fee

$953.00

DVA Fee

$953.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head and neck cancer (R).

MBS Fee

$953.00

DVA Fee

$953.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body FDG PET study performed for the evaluation of patients with suspected residual head and neck cancer after definitive treatment, and who are suitable for active therapy (R).

MBS Fee

$953.00

DVA Fee

$953.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes (R).

MBS Fee

$953.00

DVA Fee

$953.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body FDG PET study for the initial staging of cancer, for a patient who is considered suitable for active therapy, if:(a) the cancer is a typically FDG-avid cancer; and(b) there is at least 10% likelihood that a PET study result will inform a significant change in management for the patientApplicable once per cancer diagnosis (R)

MBS Fee

$953.00

DVA Fee

$953.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent cancer in a patient who is undergoing, or is suitable for, active therapy, if the cancer is a typically FGD-avid cancer (R)

MBS Fee

$953.00

DVA Fee

$953.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin or non-Hodgkin lymphoma (R)

MBS Fee

$953.00

DVA Fee

$953.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin or non-Hodgkin lymphoma (R)

MBS Fee

$953.00

DVA Fee

$953.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin or non-Hodgkin lymphoma (R)

MBS Fee

$953.00

DVA Fee

$953.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body FDG PET study to assess response to second-line chemotherapy if haemopoietic stem cell transplantation is being considered for Hodgkin or non-Hodgkin lymphoma (R)

MBS Fee

$999.00

DVA Fee

$999.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable. (R)

MBS Fee

$329.00

DVA Fee

$329.00

Category

Category 5 — Diagnostic Imaging

Description

Single rest myocardial perfusion study for the assessment of the extent and severity of non‑viable myocardium, with PET, if: (a) the service is performed because the service to which item 61325 applies cannot be performed due to unavailability of thallous chloride 201 (Tl-201); and (b) the patient has left ventricular systolic dysfunction and probable or confirmed coronary artery disease; and (c) the service is performed in conjunction with a rest myocardial perfusion study using technetium-99m; and (d) the service is requested by a specialist or a consultant physician; and (e) the service is not associated with a service to which item 11704, 11705, 11707, 11714, 11729 or 11730 applies; and (f) this service and item 61325 are applicable only twice each 24 months (R)

MBS Fee

$999.00

DVA Fee

$999.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent. (R)

MBS Fee

$953.00

DVA Fee

$953.00

Category

Category 5 — Diagnostic Imaging

Description

Whole body 68Ga DOTA peptide PET study, if:(a) a gastro entero pancreatic neuroendocrine tumour is suspected on the basis of biochemical evidence with negative or equivocal conventional imaging; or(b) both:(i) a surgically amenable gastro entero pancreatic neuroendocrine tumour has been identified on the basis of conventional techniques; and(ii) the study is for excluding additional disease sites (R)

MBS Fee

$955.50

DVA Fee

$931.30

Category

Category 5 — Diagnostic Imaging

Description

LeukoScan study of the long bones and feet for suspected osteomyelitis, if:(a) the patient does not have access to ex vivo white blood cell scanning; and(b) the patient is not being investigated for other sites of infection (R)

MBS Fee

$463.80

DVA Fee

$452.05

Category

Category 5 — Diagnostic Imaging

Description

MRI—scan of head (including MRA, if performed) for tumour of the brain or meninges (R) (Contrast) (Anaes.)

MBS Fee

$463.80

DVA Fee

$452.05

Category

Category 5 — Diagnostic Imaging

Description

MRI—scan of head (including MRA, if performed) for inflammation of brain or meninges (R) (Contrast) (Anaes.)

MBS Fee

$463.80

DVA Fee

$452.05

Category

Category 5 — Diagnostic Imaging

Description

MRI—scan of head (including MRA, if performed) for skull base or orbital tumour (R) (Contrast) (Anaes.)

MBS Fee

$386.55

DVA Fee

$376.75

Category

Category 5 — Diagnostic Imaging

Description

MRI—scan of head (including MRA, if performed) for stereotactic scan of brain, with fiducials in place, for the sole purpose of allowing planning for stereotactic neurosurgery (R) (Contrast) (Anaes.)

MBS Fee

$463.80

DVA Fee

$452.05

Category

Category 5 — Diagnostic Imaging

Description

MRI—scan of head (including MRA if performed) for the assessment of suitability for the treatment of medically refractory essential tremor with magnetic resonance imaging‑guided focused ultrasound Applicable once per patient per lifetime (R) (Contrast) (Anaes.)

MBS Fee

$463.80

DVA Fee

$452.05

Category

Category 5 — Diagnostic Imaging

Description

MRI—scan of head (including MRA if performed) for the post‑procedure assessment of the patient following magnetic resonance imaging‑guided focused ultrasound for the treatment of medically refractory essential tremor Applicable once per patient per lifetime (R) (Contrast) (Anaes.)

MBS Fee

$386.55

DVA Fee

$376.75

Category

Category 5 — Diagnostic Imaging

Description

MRI—scan of head (including MRA, if performed) for acoustic neuroma (R) (Contrast) (Anaes.)

MBS Fee

$412.25

DVA Fee

$401.80

Category

Category 5 — Diagnostic Imaging

Description

MRI—scan of head (including MRA, if performed) for pituitary tumour (R) (Contrast) (Anaes.)

MBS Fee

$463.80

DVA Fee

$452.05

Category

Category 5 — Diagnostic Imaging

Description

MRI—scan of head (including MRA, if performed) for toxic or metabolic or ischaemic encephalopathy (R) (Contrast) (Anaes.)

MBS Fee

$463.80

DVA Fee

$452.05

Category

Category 5 — Diagnostic Imaging

Description

MRI—scan of head (including MRA, if performed) for demyelinating disease of the brain (R) (Contrast) (Anaes.)

MBS Fee

$463.80

DVA Fee

$452.05

Category

Category 5 — Diagnostic Imaging

Description

MRI—scan of head (including MRA, if performed) for congenital malformation of the brain or meninges (R) (Contrast) (Anaes.)

← Prev 91 92 93 94 95 Next →

50 items per page · tap/click any row to expand